Crossmark

Characterization for the Similarity Assessment Between the Proposed Biosimilar SB17 and Ustekinumab Reference Product Using State-of-the-Art Analytical Methods

Crossref DOI link: https://doi.org/10.1007/s40268-024-00501-6

Published Online: 2025-01-16

Published Print: 2025-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yang, Sung-Yong

Lee, Changsoo

Hwang, Keumbi

Lee, Jungmin

Lee, Jaell

Hong, Juyong https://orcid.org/0000-0002-2109-0397
Jung, Seongyoung
License Information

Text and Data Mining valid from 2025-01-16

Version of Record valid from 2025-01-16
More Information

Article History

Accepted: 2 December 2024

First Online: 16 January 2025

Declarations

:

: This work was funded by Samsung Bioepis Co., Ltd., Incheon, Republic of Korea.

: All authors are employees of either Samsung Bioepis Co., Ltd. or an organization contracted by Samsung Bioepis Co., Ltd. in the present study. There are no other relationships or activities that could appear to influence the submitted work.

: This article does not contain any studies with human participants or animals. All laboratory health and safety procedures have been complied with in the course of conducting this experimental work.

: Not applicable.

: Not applicable.

: The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

: Not applicable.

: Sung-Yong Yang and Changsoo Lee contributed to collection, analysis and interpretation of the data, and drafting and revision of the manuscript. Keumbi Hwang contributed to method development and testing. Jungmin Lee and Jaell Lee contributed to data discussion and reviewed manuscript. Jooyong Hong and Seongyoung Jung contributed to study design and assessment plan and development and authoring of the manuscript.

Document is current

Any future updates will be listed below